Ann: Immutep expands Part A of TACTI-002 due to positive data, page-9

from https://www.ncbi.nlm.nih.gov/pubmed/26800463
Pembrolizumab was approved by the US FDA for the treatment of advanced or metastatic NSCLC whose disease has progressed after other treatments and with tumors that express PD-L1. In the phase I KEYNOTE-001 trial, the overall response rate (ORR) was 19.4%, the median progression-free survival (PFS) and overall survival (OS) were 3.7 months and 12.0 months for 495 unselected NSCLC patients. Strong PD-L1 expression (≥ 50%) was associated with higher ORR, longer PFS, and longer OS. The phase II/III randomized KEYNOTE-010 trial demonstrated that pembrolizumab improved OS versus docetaxel in patients with previously treated NSCLC.

So in combo it looks like about 41% v 19%??? (These stats are not comparable, but offers some context. First thing I found on-line.)

Sounds really good to me all the same. As much as I would love to see a silver bullet 100% miracle cure.